Clinical Trials Logo

Advanced Cancer clinical trials

View clinical trials related to Advanced Cancer.

Filter by:

NCT ID: NCT04945928 Active, not recruiting - Advanced Cancer Clinical Trials

Safety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLC

Start date: August 27, 2021
Phase: N/A
Study type: Interventional

Lung cancer is one of the most common malignant tumors worldwide and the mortality ranks first in the world. In recent years, with the development of targeted therapy and immunotherapy, the overall survival of lung cancer patients has improved significantly. However, the inoperable advanced tumor remains the main reason for the poor prognosis of lung cancer. Thus, we aim to carry out this single-arm, prospective study to evaluate the safety and feasibility of surgery after conversion therapy for locally advanced and advanced non-small cell lung cancer.

NCT ID: NCT04942756 Active, not recruiting - Cancer Clinical Trials

GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.

Start date: June 30, 2021
Phase: N/A
Study type: Interventional

Cancer patients with known or newly diagnosed (i.e. iatrogenic) Diabetes Mellitus (DM) in Palliative/Supportive Care will be enrolled. Patients will be randomly assigned to one of two groups. Patients included in the first group will monitor glucose levels through Continuous Glucose Monitoring (CGM), using the FreeStyle Libre 2 (FSL2). The second group is represented by the usual standard way for blood glucose (BG) monitoring (lancing device for finger samples). An interim analysis is foreseen when the half of the expected events (hyperglycemic peaks) will be observed. In case the results of interim analysis show superiority of the CGM (FSL2) group patients of the second group will be switched.

NCT ID: NCT04864418 Active, not recruiting - Advanced Cancer Clinical Trials

AST-021p Study in Advanced Solid Tumors

Start date: June 9, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and optimal Immunogenic dose of therapeutic cancer vaccine (AST-021p) in patients With advanced solid tumors A phase 1 study

NCT ID: NCT04861987 Active, not recruiting - Advanced Cancer Clinical Trials

A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors

Start date: June 18, 2021
Phase: Phase 1
Study type: Interventional

This study is an open label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are candidates for fluoropyrimidine monotherapy.

NCT ID: NCT04837196 Active, not recruiting - Advanced Cancer Clinical Trials

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Start date: December 6, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and clinical response of ASP7517, and determine the Recommended Phase 2 Dose (RP2D) and/or the Maximum Tolerated Dose (MTD) of ASP7517 when administered as a single agent and in combination with pembrolizumab. This study will also evaluate other measures of anticancer activity of ASP7517 when administered as a single agent and in combination with pembrolizumab based on central and local assessment.

NCT ID: NCT04435444 Active, not recruiting - Advanced Cancer Clinical Trials

Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer

Start date: June 15, 2020
Phase: N/A
Study type: Interventional

This study will compare the effectiveness of the Masterful supportive care intervention with that of the non-faith-based active control supportive care intervention, which uses the American Cancer Society's patient education materials, for Muslim patients who have advanced cancers. All 3 sessions may occur within one week or over multiple weeks (nonconsecutively), depending on the participants preference. The participant will have up to 12 weeks from recruitment to complete all sessions and follow up surveys.

NCT ID: NCT04339062 Active, not recruiting - Advanced Cancer Clinical Trials

Cemiplimab in AlloSCT/SOT Recipients With CSCC

CONTRAC
Start date: November 3, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

In this research study, Cemiplimab is being evaluated as a treatment for advanced cutaneous squamous cell carcinoma in participants who have previously received an allogeneic hematopoietic stem cell transplant or kidney transplant. - This research study involves the following drug(s): - Cemiplimab - Everolimus or Sirolimus - Prednisone

NCT ID: NCT04330664 Active, not recruiting - Metastatic Cancer Clinical Trials

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Start date: April 22, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.

NCT ID: NCT04310345 Active, not recruiting - Advanced Cancer Clinical Trials

Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents

Start date: March 31, 2021
Phase: N/A
Study type: Interventional

This study will evaluate the effects of human-animal interaction on reducing anxiety, depression, worry, and pain and enhancing quality of life in children ages 8-17 years old with a life threatening cancer and their parent caregivers.

NCT ID: NCT04270864 Active, not recruiting - Advanced Cancer Clinical Trials

Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

PRIMO
Start date: April 10, 2020
Phase: Phase 1
Study type: Interventional

Open label, phase Ib study of intratumoral tilsotolimod in combination with intratumoral ipilimumab and intravenous nivolumab. The trial will be divided into two parts: PART A: the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies PART B: the second part will include 3 expansion cohorts of 15 patients: - B1: anti-PD-1 refractory advanced NSCLC cohort - B2: anti-PD-1 refractory advanced melanoma cohort - B3: immunotherapy naïve microsatellite stable colorectal cancer (MSS CRC) cohort